Nan Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nan Du has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Analeise Guild
Global Gastroschisis Foundation, USA
3 shared publications - Andrea Gilbaugh
Clinical Nutrition, Stanford Medicine Children's Health, Palo Alto, California, USA
3 shared publications - James Thomas Brenna
University of Texas at Austin, USA
3 shared publications Jocelyn A. Silvester
Division of Gastroenterology, Hepatology and Nutrition Boston Children's Hospital Boston Massachusetts USA
3 shared publications- John Kerner
Division of Gastroenterology, Hepatology, and Nutrition and Division of Neonatology and Developmental Medicine, Stanford University Medical Center, Palo Alto CA, USA
3 shared publications - Michael I. Goran
Division of Endocrinology, Diabetes and Metabolism, Department of Pediatrics Children's Hospital Los Angeles Los Angeles California USA
3 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by Wiley in JPGN Reports
- Vol. 7 (4) , 620
Letter to Editor: Methodological constraints in assessing dietary and urinary molybdenum
- 5 July 2026
- Published by Wiley in JPGN Reports
- Vol. 7 (4) , 620
Open AccessLetter to Editor: Methodological constraints in assessing dietary and urinary molybdenum
- 24 March 2026
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 123 (5) , 101295
The 2025–2030 dietary guidelines for Americans: a pediatric review of recommendations for children under 5 years
- 24 March 2026
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 123 (5) , 101295
The 2025–2030 dietary guidelines for Americans: a pediatric review of recommendations for children under 5 years
- Open Access
- 26 December 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (2) , 315-322
Return to baseline arsenic concentrations after 1 year on gluten‐free diet in children with celiac disease: A prospective cohort study
Objectives: Lifelong adherence to a gluten‐free diet (GFD) is the primary treatment for celiac disease (CeD). Concerns have been raised about increased exposure to contaminants in a GFD because rice, which naturally bioaccumulates arsenic and other environmental contaminants, is commonly used as a substitute for gluten. In this study, we aimed to determine whether elevated urinary arsenic and other heavy metal concentrations, previously observed after 6 months on a GFD, persisted after 12 months on a GFD. Methods: Single‐center prospective longitudinal cohort study of children (age 2–18 years) with biopsy‐confirmed CeD who initiated a GFD between January and May 2022. The primary outcome was the change in urinary arsenic concentration between baseline diagnostic endoscopy and 12 months on a GFD. Results: Twenty‐one of the 35 (60%) participants provided a follow‐up sample. After 12 months on a GFD, total median urinary arsenic concentration returned to baseline (3.42 vs. 4.93 μg/L, p = 0.17). The median total nail arsenic collection did not differ significantly between endoscopy and 12 months on a GFD samples ( p = 0.56). Only urinary molybdenum concentration was increased between endoscopy and 12 months of a GFD. Conclusions: Children with CeD may have increased arsenic exposure as they transition to a GFD, but concentrations return to baseline within 1 year. Future studies are needed to identify dietary contributors and guide strategies to limit excess arsenic exposure.
- 26 December 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (2) , 315-322
Open AccessReturn to baseline arsenic concentrations after 1 year on gluten‐free diet in children with celiac disease: A prospective cohort study
Objectives: Lifelong adherence to a gluten‐free diet (GFD) is the primary treatment for celiac disease (CeD). Concerns have been raised about increased exposure to contaminants in a GFD because rice, which naturally bioaccumulates arsenic and other environmental contaminants, is commonly used as a substitute for gluten. In this study, we aimed to determine whether elevated urinary arsenic and other heavy metal concentrations, previously observed after 6 months on a GFD, persisted after 12 months on a GFD. Methods: Single‐center prospective longitudinal cohort study of children (age 2–18 years) with biopsy‐confirmed CeD who initiated a GFD between January and May 2022. The primary outcome was the change in urinary arsenic concentration between baseline diagnostic endoscopy and 12 months on a GFD. Results: Twenty‐one of the 35 (60%) participants provided a follow‐up sample. After 12 months on a GFD, total median urinary arsenic concentration returned to baseline (3.42 vs. 4.93 μg/L, p = 0.17). The median total nail arsenic collection did not differ significantly between endoscopy and 12 months on a GFD samples ( p = 0.56). Only urinary molybdenum concentration was increased between endoscopy and 12 months of a GFD. Conclusions: Children with CeD may have increased arsenic exposure as they transition to a GFD, but concentrations return to baseline within 1 year. Future studies are needed to identify dietary contributors and guide strategies to limit excess arsenic exposure.
- Open Access
- 23 November 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (1) , 118-126
Autoantibody signatures in children with celiac disease, juvenile idiopathic arthritis, and polyautoimmunity
Objective: To determine if multiplex autoantibody arrays can identify novel biomarker signatures in children with one or multiple autoimmune diseases (polyautoimmunity). Methods: Plasma collected from children (18 years or younger) in the Boston Children's Hospital Precision Link Biobank for Health Discovery between January 2007 and June 2021 was analyzed using a microarray with 120 autoantigens associated with various autoimmune diseases to assess for both immunoglobulin G (IgG) and A (IgA) autoantibodies. To determine if disease‐specific, we binary classified those with polyautoimmunity and the most common autoimmune diseases in our cohort (autoimmune thyroid disease, type 1 diabetes, or celiac disease [CeD]). For each comparison within and between groups, the autoantibody intensity was releveled to the control and a linear model was fit. Results: Plasma was analyzed from 114 children with either CeD ( n = 31), juvenile idiopathic arthritis ( n = 20), polyautoimmunity ( n = 31), or no autoimmune disease ( n = 32). Overall, children with polyautoimmunity had higher levels of specific autoantibodies relative to the other groups. Children with CeD and polyautoimmunity expressed higher levels of H/K ATPase IgA and IgG and MDA5 IgG compared to those with CeD alone. Conclusions: Use of multiplex antigen arrays in patients with and without polyautoimmunity is a valuable tool to identify known and potentially novel disease‐antigens. Further study is needed to determine the role of H/K ATPase autoantibodies in monitoring of CeD patients.
- 23 November 2025
- Published by Wiley in JPGN Reports
- Vol. 7 (1) , 118-126
Open AccessAutoantibody signatures in children with celiac disease, juvenile idiopathic arthritis, and polyautoimmunity
Objective: To determine if multiplex autoantibody arrays can identify novel biomarker signatures in children with one or multiple autoimmune diseases (polyautoimmunity). Methods: Plasma collected from children (18 years or younger) in the Boston Children's Hospital Precision Link Biobank for Health Discovery between January 2007 and June 2021 was analyzed using a microarray with 120 autoantigens associated with various autoimmune diseases to assess for both immunoglobulin G (IgG) and A (IgA) autoantibodies. To determine if disease‐specific, we binary classified those with polyautoimmunity and the most common autoimmune diseases in our cohort (autoimmune thyroid disease, type 1 diabetes, or celiac disease [CeD]). For each comparison within and between groups, the autoantibody intensity was releveled to the control and a linear model was fit. Results: Plasma was analyzed from 114 children with either CeD ( n = 31), juvenile idiopathic arthritis ( n = 20), polyautoimmunity ( n = 31), or no autoimmune disease ( n = 32). Overall, children with polyautoimmunity had higher levels of specific autoantibodies relative to the other groups. Children with CeD and polyautoimmunity expressed higher levels of H/K ATPase IgA and IgG and MDA5 IgG compared to those with CeD alone. Conclusions: Use of multiplex antigen arrays in patients with and without polyautoimmunity is a valuable tool to identify known and potentially novel disease‐antigens. Further study is needed to determine the role of H/K ATPase autoantibodies in monitoring of CeD patients.
- Open Access
- 5 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 2, Regulatory and Safety Considerations
Operation Stork Speed was launched to modernize infant formula oversight after 2022 shortages and other evidence of supply chain and safety issues. Current Food and Drug Administration(FDA) processes to regulate formula are at times slow and complex, making it difficult for new formulas to enter the market. One key pathway to adding bioactive substances or other compounds to infant formula is via the Generally Recognized as Safe (GRAS) route. GRAS and food additive pathways require safety data, but food additive petitions require more safety information and cannot be marketed until FDA approval is granted. Concern has been expressed about the safety of formula related to the possible presence of toxic substances in formula. Heavy metals, PFAS and other toxins can be found in formulas and infants can be at increased risk of effects. US lacks enforceable limits, unlike EU, Canadian and Australian counterparts. To enhance the regulatory environment for infant formula, legislative updates, supply chain transparency and alignment with global safety standards are needed.
- 5 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 2, Regulatory and Safety Considerations
Operation Stork Speed was launched to modernize infant formula oversight after 2022 shortages and other evidence of supply chain and safety issues. Current Food and Drug Administration(FDA) processes to regulate formula are at times slow and complex, making it difficult for new formulas to enter the market. One key pathway to adding bioactive substances or other compounds to infant formula is via the Generally Recognized as Safe (GRAS) route. GRAS and food additive pathways require safety data, but food additive petitions require more safety information and cannot be marketed until FDA approval is granted. Concern has been expressed about the safety of formula related to the possible presence of toxic substances in formula. Heavy metals, PFAS and other toxins can be found in formulas and infants can be at increased risk of effects. US lacks enforceable limits, unlike EU, Canadian and Australian counterparts. To enhance the regulatory environment for infant formula, legislative updates, supply chain transparency and alignment with global safety standards are needed.
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants
The U.S. formula industry utilizes aggressive marketing strategies which exploit parental anxieties, undermine breastfeeding, violate ethical international standards, all of which contribute to early formula introduction and disparities in breastfeeding. Additionally, misleading or complex labeling contribute to caregiver and provider confusion regarding the content of formulas. A centralized, Food and Drug Administration (FDA)-maintained database of infant formulas could support caregivers and healthcare professionals in countering misinformation and making evidence-based decisions. Human milk remains the gold standard for infant nutrition, with strong evidence supporting its role in reducing morbidity and mortality, especially in the Neonatal Intensive Care Unit (NICU). Despite this, disparities persist in breastfeeding rates, particularly among Black and Hispanic mothers. These are driven by structural barriers, including lack of paid parental leave and inadequate lactation support. Donor human milk (DHM) is the recommended alternative for high-risk infants in the NICU when mother’s own milk (MOM) is unavailable. However, due to lack of federal funding and oversight, high cost and inconsistent insurance coverage, the use of DHM use is limited, especially in safety-net hospitals. Specialized hypoallergenic and metabolic formulas are essential for managing medical conditions including cow’s milk-protein allergy and inborn errors of metabolism. These are regulated as exempt formulas but must meet rigorous clinical standards. In the NICU, adequate early nutrition for preterm infants is crucial to reduce morbidity and mortality and improve long-term neurodevelopmental outcomes. Human milk fortifiers (HMFs) are composed of similar ingredients as infant formula and are used to improve the nutritional content feedings given in the NICU and post-discharge. The use of live biotherapeutic products (LBPs) or probiotics as additives to preterm infants have been demonstrated in multiple studies to reduce the incidence of NEC, late-onset sepsis, and all-cause mortality.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants
The U.S. formula industry utilizes aggressive marketing strategies which exploit parental anxieties, undermine breastfeeding, violate ethical international standards, all of which contribute to early formula introduction and disparities in breastfeeding. Additionally, misleading or complex labeling contribute to caregiver and provider confusion regarding the content of formulas. A centralized, Food and Drug Administration (FDA)-maintained database of infant formulas could support caregivers and healthcare professionals in countering misinformation and making evidence-based decisions. Human milk remains the gold standard for infant nutrition, with strong evidence supporting its role in reducing morbidity and mortality, especially in the Neonatal Intensive Care Unit (NICU). Despite this, disparities persist in breastfeeding rates, particularly among Black and Hispanic mothers. These are driven by structural barriers, including lack of paid parental leave and inadequate lactation support. Donor human milk (DHM) is the recommended alternative for high-risk infants in the NICU when mother’s own milk (MOM) is unavailable. However, due to lack of federal funding and oversight, high cost and inconsistent insurance coverage, the use of DHM use is limited, especially in safety-net hospitals. Specialized hypoallergenic and metabolic formulas are essential for managing medical conditions including cow’s milk-protein allergy and inborn errors of metabolism. These are regulated as exempt formulas but must meet rigorous clinical standards. In the NICU, adequate early nutrition for preterm infants is crucial to reduce morbidity and mortality and improve long-term neurodevelopmental outcomes. Human milk fortifiers (HMFs) are composed of similar ingredients as infant formula and are used to improve the nutritional content feedings given in the NICU and post-discharge. The use of live biotherapeutic products (LBPs) or probiotics as additives to preterm infants have been demonstrated in multiple studies to reduce the incidence of NEC, late-onset sepsis, and all-cause mortality.
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 1, Nutrient Considerations
Operation Stork Speed, launched by the Food and Drug Administration(FDA) in March 2025, represents a comprehensive initiative to update infant formula regulations that have remained largely unchanged since the 1980’s. This expert panel review addresses recommendations for nutrients considering four decades of accumulated scientific evidence since then. Current FDA fatty acid regulations specify only total fat content and minimum linoleic acid requirements despite substantial international consensus on polyunsaturated fatty acid specifications. Evidence strongly supports establishing maximum linoleic acid levels and docosahexaenoic acid (DHA) and arachidonic acid (ARA) requirements, reflecting the critical role of omega-3 fatty acids in neurocognitive development and visual acuity. The panel emphasizes that saturated and monounsaturated fatty acids comprise over 80% of human milk fatty acids, while acknowledging recent concerns about seed oils and supporting balanced PUFA formulations. Carbohydrate composition presents significant concerns, as over half of US formulas contain glucose polymers (e.g. corn syrup solids) despite lactose being the primary carbohydrate energy source in human milk. Observational studies link corn syrup-based formulas to multiple possible health risks, including excess weight gain, warranting reconsideration of the value of non-lactose carbohydrate substitutions in formulas for healthy children. Protein content recommendations support decreasing the upper range of allowable intake, aligning with European standards and addressing concerns about excessive protein intake contributing to later obesity risk. Micronutrient evaluation reveals the need to reduce the iron content in routine formulas to lower levels, consistent with European Food Safety Authority recommendations and emerging safety data and a need to set upper limits for the concentration of calcium and phosphorus. Overall, infant formula is a healthy product and has many decades of successfully feeding infants. These comprehensive updates aim to more closely align US infant formula regulations with current scientific understanding and international standards while supporting optimal infant growth, development, and long-term health outcomes.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 1, Nutrient Considerations
Operation Stork Speed, launched by the Food and Drug Administration(FDA) in March 2025, represents a comprehensive initiative to update infant formula regulations that have remained largely unchanged since the 1980’s. This expert panel review addresses recommendations for nutrients considering four decades of accumulated scientific evidence since then. Current FDA fatty acid regulations specify only total fat content and minimum linoleic acid requirements despite substantial international consensus on polyunsaturated fatty acid specifications. Evidence strongly supports establishing maximum linoleic acid levels and docosahexaenoic acid (DHA) and arachidonic acid (ARA) requirements, reflecting the critical role of omega-3 fatty acids in neurocognitive development and visual acuity. The panel emphasizes that saturated and monounsaturated fatty acids comprise over 80% of human milk fatty acids, while acknowledging recent concerns about seed oils and supporting balanced PUFA formulations. Carbohydrate composition presents significant concerns, as over half of US formulas contain glucose polymers (e.g. corn syrup solids) despite lactose being the primary carbohydrate energy source in human milk. Observational studies link corn syrup-based formulas to multiple possible health risks, including excess weight gain, warranting reconsideration of the value of non-lactose carbohydrate substitutions in formulas for healthy children. Protein content recommendations support decreasing the upper range of allowable intake, aligning with European standards and addressing concerns about excessive protein intake contributing to later obesity risk. Micronutrient evaluation reveals the need to reduce the iron content in routine formulas to lower levels, consistent with European Food Safety Authority recommendations and emerging safety data and a need to set upper limits for the concentration of calcium and phosphorus. Overall, infant formula is a healthy product and has many decades of successfully feeding infants. These comprehensive updates aim to more closely align US infant formula regulations with current scientific understanding and international standards while supporting optimal infant growth, development, and long-term health outcomes.
- 15 May 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (1) , 5-10
New international infant formulas in the United States: Understanding the Food and Drug Administration‐enforcement discretion
Take Away Points: Most of the international formulas that were approved through Food and Drug Administration enforcement discretion are safe and appropriate for the majority of full‐term infants. Given that many of these international formulas may be purchased on websites sold by third‐party vendors, and may be in Stages rather than inclusive from 0 to 12 months, it is important to clarity where the formula is being purchased from. Many of the international formulas use different mixing ratios, so it is important that parents read the label to confirm proper mixing instructions.
- 15 May 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (1) , 5-10
New international infant formulas in the United States: Understanding the Food and Drug Administration‐enforcement discretion
Take Away Points: Most of the international formulas that were approved through Food and Drug Administration enforcement discretion are safe and appropriate for the majority of full‐term infants. Given that many of these international formulas may be purchased on websites sold by third‐party vendors, and may be in Stages rather than inclusive from 0 to 12 months, it is important to clarity where the formula is being purchased from. Many of the international formulas use different mixing ratios, so it is important that parents read the label to confirm proper mixing instructions.
- Open Access
- 23 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Heavy metal exposures in aerodigestive clinic cohort of infants with reflux or dysphagia
Infant cereals (rice/oatmeal), purees, and anti-reflux formulas are often first line treatments for thickening in infants with reflux and oropharyngeal dysphagia. However, there has been growing concern about heavy metal contamination, especially arsenic, in these commonly used thickeners. This is a particular concern in infants who may be more susceptible to heavy metal neurotoxicity. The study aimed to assess whether there are differences in heavy metal levels, particularly arsenic, in infants with reflux or oropharyngeal dysphagia while on different thickeners. We performed a single center study in infants (< 1 year of age) with diagnosis of reflux or oropharyngeal dysphagia who were seen between December 2021–2023. Participants submitted urine samples and completed dietary questionnaires to assess their elemental exposures. The primary outcome of interest was urinary arsenic concentrations, though other elements were also measured. Of the 56 infants, 27 were on gelmix® or purees, 19 were on Enfamil AR and 10 were on infant oatmeal/rice cereal as a thickener. The median total urinary arsenic concentration did not differ between groups (p = 0.086) and levels between groups were well below the Agency for Toxic Substances and Disease Registry (ATSDR)’s toxicity limits. Infants with higher number of servings of alternative arsenic sources via their solid food were more likely to have higher urinary arsenic level (p = 0.001), suggesting a potential need for the FDA to implement stricter food supply regulations. Only molybdenum had significant difference in levels between thickeners (p = 0.0012). Even in high-risk patients, urinary arsenic concentrations did not differ between thickener groups.
- 23 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessHeavy metal exposures in aerodigestive clinic cohort of infants with reflux or dysphagia
Infant cereals (rice/oatmeal), purees, and anti-reflux formulas are often first line treatments for thickening in infants with reflux and oropharyngeal dysphagia. However, there has been growing concern about heavy metal contamination, especially arsenic, in these commonly used thickeners. This is a particular concern in infants who may be more susceptible to heavy metal neurotoxicity. The study aimed to assess whether there are differences in heavy metal levels, particularly arsenic, in infants with reflux or oropharyngeal dysphagia while on different thickeners. We performed a single center study in infants (< 1 year of age) with diagnosis of reflux or oropharyngeal dysphagia who were seen between December 2021–2023. Participants submitted urine samples and completed dietary questionnaires to assess their elemental exposures. The primary outcome of interest was urinary arsenic concentrations, though other elements were also measured. Of the 56 infants, 27 were on gelmix® or purees, 19 were on Enfamil AR and 10 were on infant oatmeal/rice cereal as a thickener. The median total urinary arsenic concentration did not differ between groups (p = 0.086) and levels between groups were well below the Agency for Toxic Substances and Disease Registry (ATSDR)’s toxicity limits. Infants with higher number of servings of alternative arsenic sources via their solid food were more likely to have higher urinary arsenic level (p = 0.001), suggesting a potential need for the FDA to implement stricter food supply regulations. Only molybdenum had significant difference in levels between thickeners (p = 0.0012). Even in high-risk patients, urinary arsenic concentrations did not differ between thickener groups.
- Open Access
- 20 October 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (4) , 470-474
Identifying parentally perceived barriers for children with celiac disease to participate in elementary school meal programs
Several states have recently enacted laws permanently granting all public school students access to free breakfast and lunch. However, children with dietary restrictions, such as celiac disease (CeD), may encounter barriers to participation in these meal programs. We surveyed caregivers of school‐aged children with CeD to study barriers to universal school meals. More than half of the children with CeD did not participate in school meal programs due to concerns about the cafeteria's ability to prepare gluten‐free (GF) meals safely. Moreover, among those who were food insecure and GF food insecure, 50% had never consumed free school lunch and breakfast. Parental perception of nutritional quality, communication regarding GF options, and safety of school kitchens emerged as common obstacles to participation in these programs. Addressing these concerns is paramount to ensuring equitable access to nutritious meals for all students.
- 20 October 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (4) , 470-474
Open AccessIdentifying parentally perceived barriers for children with celiac disease to participate in elementary school meal programs
Several states have recently enacted laws permanently granting all public school students access to free breakfast and lunch. However, children with dietary restrictions, such as celiac disease (CeD), may encounter barriers to participation in these meal programs. We surveyed caregivers of school‐aged children with CeD to study barriers to universal school meals. More than half of the children with CeD did not participate in school meal programs due to concerns about the cafeteria's ability to prepare gluten‐free (GF) meals safely. Moreover, among those who were food insecure and GF food insecure, 50% had never consumed free school lunch and breakfast. Parental perception of nutritional quality, communication regarding GF options, and safety of school kitchens emerged as common obstacles to participation in these programs. Addressing these concerns is paramount to ensuring equitable access to nutritious meals for all students.